Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $23.43 Average PT from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $23.43.

Several research firms have recently weighed in on TEVA. Bank of America cut their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday, March 27th. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Finally, Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently modified their holdings of TEVA. Pathstone Holdings LLC boosted its position in Teva Pharmaceutical Industries by 6.5% during the third quarter. Pathstone Holdings LLC now owns 72,598 shares of the company’s stock valued at $1,308,000 after purchasing an additional 4,452 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $439,000. Charles Schwab Investment Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 24.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 899,175 shares of the company’s stock worth $16,203,000 after purchasing an additional 177,836 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 10.0% in the 3rd quarter. Daiwa Securities Group Inc. now owns 89,465 shares of the company’s stock valued at $1,612,000 after buying an additional 8,100 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Teva Pharmaceutical Industries by 5.9% during the third quarter. The Manufacturers Life Insurance Company now owns 432,402 shares of the company’s stock worth $7,792,000 after buying an additional 24,248 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 2.0 %

Shares of NYSE:TEVA opened at $15.39 on Friday. The company has a 50 day moving average price of $17.08 and a two-hundred day moving average price of $18.11. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a market capitalization of $17.44 billion, a PE ratio of -10.61, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries has a 52 week low of $12.51 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.